Particle Therapy Market Research Report – Global Forecast till 2027

Particle Therapy Market Size, Growth and Trends Analysis by Type (Proton Therapy & Heavy Ion Therapy), Product & Service (Products & Others), Cancer Type (Prostate, Lung), System (Multi-Room & Single Room), Application (Treatment & Research) — Forecast till 2027

ID: MRFR/MED/5535-HCR | January 2023 | Region: Global | 85 Pages         

Particle Therapy Market

Particle Therapy Market is accounted for USD 1.1 billion and expected to register 7.4% CAGR during the forecast period

Segmentation
By Type Proton Therapy & Heavy Ion Therapy
By Product & Service Products & Others
By Cancer Type Prostate Lung
By System Multi-Room & Single Room
By Application Treatment & Research
Key Players
Companies Profiled   Advanced Oncotherapy PLC.    Danfysik A/S    Hitachi    Ltd.    Ion Beam Applications Sa (IBA)    Mevion Medical Systems    Inc.    Optivus Proton Therapy    Protom International    Provision Healthcare    LLC    Sumitomo Heavy Industries    Varian Medical Systems
Drivers
Market Driving Forces   rising prevalence of cancer population    low risk of treatment induced disorders    rising number of particle therapy centers
Request a Free Sample

Particle Therapy Market Overview The Particle Therapy Market is accounted for USD 790.45 million in 2017 and expected to register 9.1% CAGR during the forecast period. Particle therapy is one of the most advanced types of external beam radiation therapy for oncology in the world. This method saves more healthy radiation tissue than traditional photon therapy. These particles have better physical intrinsic qualities, lowering the intake dose to about half of what a clinically appropriate target would be. The market is predicted to develop because of the rising prevalence of cancer, low risk of treatment-induced illnesses, the opportunity for retreatment due to low radiation dose, and the growing number of particle therapy facilities around the world. Furthermore, increased R&D spending and aggressive methods used by leading companies, such as new product releases, are driving market expansion. The advantages gave by particle therapy, as well as the rising global occurrence of cancer, are driving market expansion. A major driving element for this market has been discovered to be the number of persons suffering from various cancers. Cancer is one of the most common life-threatening diseases nowadays. Cancer kills around 70% of people in low and middle-income nations. Because particle treatments are used to treat cancer, their increasing prevalence is projected to be a major driver of market expansion.

Particle Therapy Market Segmentation:


The Global Particle Therapy Market has been segmented on the basis of type, product & service, cancer type, system, and application.On the basis of type, the market has been classified as proton therapy and heavy ion therapy. The market, by product and services, has been segmented into products and services. Products are further segmented into cyclotrons, synchrotrons, and synchrocyclotrons. Based on cancer type, the market has been segmented into prostate cancer, lung cancer, pediatric cancer, head and neck cancer, breast cancer, and others. The market, by system, has been segmented into multi-room systems and single-room systems. On the basis of application, the market has been classified as treatment applications and research applications. The pediatric cancer segment is expected to hold the largest market share of the particle therapy market, by cancer type, during the forecast period. Also, research applications to register the highest CAGR in the global market during the forecast period.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European particle therapy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The particle therapy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The particle therapy market in the Middle East & Africa has been segmented into the Middle East and Africa.


Regional Market Summary


Global Particle Therapy Market Share, by Region, 2017 (%) Particle Therapy Market Share


Source: MRFR Analysis


The Americas are likely to dominate the global particle therapy market owing to the rising prevalence of cancer patient, increasing funding & investments by manufacturer, and government focused for establishment of centers for treatment. According to the U.S. Department of Health and Human Services, in 2018, around 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease.


The European market is expected to be the second-largest Particle Therapy market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, favorable reimbursement policies in European countries are contributing to the growth of the market in this region.


Asia-Pacific is expected to be the fastest-growing particle therapy market during the forecast period owing to the increasing prevalence of cancer, rising investments in healthcare and expansions by market players in the region. Also, country such as India and China are considering fastest growing region due to the presence of huge patient population. Moreover, the government of these countries are open to adopt new technology, and best treatment option from a developed country. According to the International Agency for Research on Cancer, in 2018, India has a prevalence of 173.5 cancer patients per 100,000 population. Moreover, in China, the prevalence rate of cancer was 377.6 patients per 100,000 population in 2018.


The market in the Middle East & Africa is expected to account for the smallest share of the global Particle Therapy market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.


Key Players


Some of the key players in the global particle therapy market are Advanced Oncotherapy PLC., Danfysik A/S, Hitachi, Ltd., Ion Beam Applications Sa (IBA), Mevion Medical Systems, Inc., Optivus Proton Therapy, Inc., Protom International, Inc., Provision Healthcare, LLC, Sumitomo Heavy Industries, Ltd., Varian Medical Systems, Inc.


Global Particle Therapy Market, by Type:



  • Proton Therapy

  • Heavy Ion Therapy


Global Particle Therapy Market, by Product & Service:



  • Products


    • Cyclotrons

    • Synchrotrons

    • Synchrocyclotrons


  • Services


Global Particle Therapy Market, by Cancer Type:



  • Prostate Cancer

  • Lung Cancer

  • Pediatric Cancer

  • Head and Neck Cancer

  • Breast Cancer

  • Others


Global Particle Therapy Market, by System:



  • Multi-Room Systems

  • Single-Room Systems


Global Particle Therapy Market, by Application:



  • Treatment Applications

  • Research Applications


Global Particle Therapy Market, by Region:



  • Americas


    • North America


      • US

      • Canada


    • South America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Company Profiles:    



  • Advanced Oncotherapy PLC.

  • Danfysik A/S

  • Hitachi, Ltd.

  • Ion Beam Applications Sa (IBA)

  • Mevion Medical Systems, Inc.

  • Optivus Proton Therapy, Inc.

  • Protom International, Inc.

  • Provision Healthcare, LLC

  • Sumitomo Heavy Industries, Ltd.

  • Varian Medical Systems, Inc.

  • Others


Recent Development


Advanced Oncotherapy plc stated in December 2017 that it has secured new finance of USD 46.75 million, with USD 37.5 million coming from a new Chinese investor. During the assessment period, the lack of an acceptable reimbursement mechanism and the significant expenditures associated with the development of these centers may stifle particle therapy market expansion. In 2017, Mitsubishi Electric agreed to sell its particle therapy systems business to Hitachi and merge the two companies into one. Hitachi was able to strengthen its position in the proton therapy business as a result of this. The first compact proton therapy system in the Middle East was developed by Royal Philips (US) and Proton Partners International (UK) in collaboration with IBA (Belgium).Intended Audience:

  • Medical devices manufacturers

  • Medical devices product distributors and suppliers

  • Healthcare providers

  • Research institutes and academic centers

  • Contract manufacturing organizations

  • Government associations

  • Market research and consulting



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The latest valuation of the particle therapy market in 2017 was USD 790.45 million.

The forecasted CAGR for the particle therapy market is 9.1% for the duration of 2018 to 2023.

The particle therapy market would be driven by factors like rising cases of cancer, an increasing number of particle therapy center, low risk of treatment, and potential retreatment opportunity can trigger better market growth.

The pediatric cancer segment has the opportunity to register the highest growth in the particle therapy market.

The Americas has the setup to continue their domination of the particle therapy market.